Developing high-throughput HIV incidence assay with pyrosequencing platform

Area of Science:

• Genomics
• Epidemiology
• Bioinformatics

Background:

• Monitoring human immunodeficiency virus (HIV) incidence is crucial for understanding epidemic trends and evaluating prevention strategies.
• Traditional HIV incidence assays rely on antibody detection, but advancements in sequencing technology offer new genomic approaches.
• Distinguishing recent HIV infections from chronic infections is essential for accurate epidemiological assessment.

Purpose of the Study:

• To develop a high-throughput, single-measure genomic assay for determining HIV incidence.
• To utilize pyrosequencing and bioinformatics to analyze HIV gene sequences for incidence classification.
• To establish a cost-effective and accurate method for routine HIV surveillance.

Main Methods:

• Developed a signal-masking bioinformatics pipeline for pyrosequencing data analysis.
• Analyzed 18,434 HIV envelope gene segments from incident and chronic patients.
• Cross-validated pyrosequencing results with the single-genome-amplification (SGA) method.
• Identified and utilized two genomic biomarkers for distinguishing infection status.

Main Results:

• The pyrosequencing assay achieved 100% sensitivity and 96% specificity in classifying HIV infections.
• Results were reproducible and robust across pyrosequencing and SGA platforms.
• Simulations confirmed biomarker tolerance to sequencing errors and resampling.
• Disease stage (AIDS vs. non-AIDS) did not significantly impact classification accuracy.

Conclusions:

• The high-throughput genomic HIV incidence assay is a significant advancement for single-measure incidence determination.
• This assay provides a precise and reproducible method for differentiating recent from chronic HIV infections.
• The platform's cost-effectiveness and high throughput make it suitable for large-scale surveillance efforts.